Exploration of the Antibacterial and Anti-Inflammatory Activity of a Novel Antimicrobial Peptide Brevinin-1BW

• Published in: Molecules (Basel, Switzerland) Switzerland), 2024-04, Vol.29 (7), p.1534
• Main Authors: Chen, Zhizhi, Wang, Lei, He, Dongxia, Liu, Qi, Han, Qinqin, Zhang, Jinyang, Zhang, A-Mei, Song, Yuzhu
• Format: Article
• Language: English
• Subjects: Amino acids; Anti-Bacterial Agents - pharmacology; anti-inflammation; Anti-Inflammatory Agents - pharmacology; Anti-inflammatory drugs; Antibacterial agents; Antibiotics; Antimicrobial agents; Antimicrobial Peptides; Bacteria; Bacterial infections; Biofilms; Brevinin-1; Cancer; China; Cytotoxicity; Drug resistance; Drug resistance in microorganisms; Efficiency; Gram-negative bacteria; Gram-positive bacteria; Infections; Investigations; Lipopolysaccharides; LPS; Methicillin-Resistant Staphylococcus aureus; Peptides; R&D; Recovery (Medical); Research & development; Staphylococcus aureus; Staphylococcus aureus infections
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules29071534

Antibiotic resistance has emerged as a grave threat to global public health, leading to an increasing number of treatment failures. Antimicrobial peptides (AMPs) are widely regarded as potential substitutes for traditional antibiotics since they are less likely to induce resistance when used. A novel AMP named Brevinin-1BW (FLPLLAGLAASFLPTIFCKISRKC) was obtained by the Research Center of Molecular Medicine of Yunnan Province from the skin of the . Brevinia-1BW had effective inhibitory effects on Gram-positive bacteria, with a minimum inhibitory concentration (MIC) of 3.125 μg/mL against (ATCC 29212) and 6.25 μg/mL against both (ATCC 25923) and multidrug-resistant (ATCC 29213) but had weaker inhibitory effects on Gram-negative bacteria, with a MIC of ≥100 μg/mL. Studies using scanning electron microscopy (SEM) and flow cytometry have revealed that it exerts its antibacterial activity by disrupting bacterial membranes. Additionally, it possesses strong biofilm inhibitory and eradication activities as well as significant lipopolysaccharide (LPS)-binding activity. Furthermore, Brevinin-1BW has shown a significant anti-inflammatory effect in LPS-treated RAW264.7 cells. In conclusion, Brevinin-1BW is anticipated to be a promising clinical agent with potent anti-Gram-positive bacterial and anti-inflammatory properties.